Healthcare shares are fairly flat in pre-market. Among the major
movers, shares in IntelliPharmaCeutics International Inc. (
) have spiked about 80% pre-market after the maker of controlled
and targeted-release drugs won final FDA approval of its 15 and 30
milligram formulations of dexmethylphenidate hydrochloride
The stock recently changed hands at $3.15 after hitting an
earlier high of $3.72, its best level since August 2011.
And, Medtronic (
) is down about 1% as it reports Q2 revenue of $4.19 bln, vs. the
analyst consensus of $4.17 bln on Capital IQ. Adjusted EPS was
$0.91, vs. expectations of $0.90 per share.
For FY 2014, the company continues to expect full year revenue
growth in the range of 3% to 4% on a constant currency basis and
EPS in the range of $3.80 to $3.85. The Street view is $3.82 per
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.